已发表论文

NLRP3 炎性体作为治疗心脏纤维化的新靶点

 

Authors Fan J, Ren M, Adhikari BK , Wang H, He Y

Received 12 April 2022

Accepted for publication 1 July 2022

Published 7 July 2022 Volume 2022:15 Pages 3847—3858

DOI https://doi.org/10.2147/JIR.S370483

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ning Quan

Abstract: Cardiac fibrosis often has adverse cardiovascular effects, including heart failure, sudden death, and malignant arrhythmias. However, there is no targeted therapy for cardiac fibrosis. Inflammation is known to play a crucial role in the disorder, and the NLR pyrin domain-containing-3 (NLRP3) inflammasome is closely associated with innate immunity. Therefore, further understanding the pathophysiological role of the inflammasome in cardiac fibrosis may provide novel strategies for the prevention and treatment of the disorder. The aim of this review was to summarize the present knowledge of NLRP3 inflammasome-related mechanisms underlying cardiac fibrosis and to suggest potential targeted therapy that could be used to treat the condition.
Keywords: NLRP3 inflammasome, cardiac fibrosis, AIM2, ASC, caspase-1